For example, Haffner et al. demonstrated that trastuzumab had a particularly good therapeutic effect in Her2/neu-positive gastric adenocarcinomas with a Her2/neu expression in at least 40% of the tumor cells or an (F)ISH-amplification ratio of 3 or more17. Here, ERBB2 is linked to gastric adenocarcinoma.